ID   Ma-10
AC   CVCL_7061
SY   Ma10
DR   cancercelllines; CVCL_7061
DR   Cosmic; 801596
DR   Cosmic; 844838
DR   Cosmic; 876146
DR   Cosmic; 917994
DR   Cosmic; 1239875
DR   Cosmic; 1656897
DR   Cosmic; 2125272
DR   Cosmic; 2668315
DR   IARC_TP53; 11882
DR   Wikidata; Q54903679
RX   PubMed=1650680;
RX   PubMed=9393586;
RX   PubMed=11005564;
RX   PubMed=15802814;
RX   PubMed=19472407;
RX   PubMed=20557307;
RX   PubMed=22313637;
CC   Population: Japanese.
CC   Doubling time: 75.0 hours (PubMed=1650680).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Val (c.734G>T); ClinVar=VCV000376603; Zygosity=Unspecified (PubMed=20557307).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   57Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 17
//
RX   PubMed=1650680; DOI=10.1378/chest.100.2.429;
RA   Masuda N., Fukuoka M., Takada M., Kudoh S., Kusunoki Y.;
RT   "Establishment and characterization of 20 human non-small cell lung
RT   cancer cell lines in a serum-free defined medium (ACL-4).";
RL   Chest 100:429-438(1991).
//
RX   PubMed=9393586; DOI=10.1007/s004320050101;
RA   Shimizu E., Zhao M.-R., Shinohara A., Namikawa O., Ogura T., Masuda N.,
RA   Takada M., Fukuoka M., Sone S.;
RT   "Differential expressions of cyclin A and the retinoblastoma gene
RT   product in histological subtypes of lung cancer cell lines.";
RL   J. Cancer Res. Clin. Oncol. 123:533-538(1997).
//
RX   PubMed=11005564; DOI=10.1038/sj.neo.7900094;
RA   Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M.,
RA   Yokota J.;
RT   "Mutation and expression of the DCC gene in human lung cancer.";
RL   Neoplasia 2:300-305(2000).
//
RX   PubMed=15802814; DOI=10.1248/bpb.28.707;
RA   Ikuta K., Takemura K., Sasaki K., Kihara M., Nishimura M., Ueda N.,
RA   Naito S., Lee E., Shimizu E., Yamauchi A.;
RT   "Expression of multidrug resistance proteins and accumulation of
RT   cisplatin in human non-small cell lung cancer cells.";
RL   Biol. Pharm. Bull. 28:707-712(2005).
//
RX   PubMed=19472407; DOI=10.1002/humu.21028;
RA   Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R.,
RA   Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.;
RT   "A gene-alteration profile of human lung cancer cell lines.";
RL   Hum. Mutat. 30:1199-1206(2009).
//
RX   PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x;
RA   Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.;
RT   "Prevalence of human papillomavirus 16/18/33 infection and p53
RT   mutation in lung adenocarcinoma.";
RL   Cancer Sci. 101:1891-1896(2010).
//
RX   PubMed=22313637; DOI=10.4161/cbt.19238;
RA   Takata M., Chikumi H., Miyake N., Adachi K., Kanamori Y., Yamasaki A.,
RA   Igishi T., Burioka N., Nanba E., Shimizu E.;
RT   "Lack of AKT activation in lung cancer cells with EGFR mutation is a
RT   novel marker of cetuximab sensitivity.";
RL   Cancer Biol. Ther. 13:369-378(2012).
//